Vascular response after zilver PTX stent implantation for superficial femoral artery lesions: Serial optical coherence tomography findings at 6 and 12 months

Journal of Endovascular Therapy

Volumn 22, Issue 1, 2015, Pages 41-47

  Tomoi, Yusuke ^a   Kuramitsu, Shoichi ^a   Soga, Yoshimitsu ^a   Aihara, Hideaki ^b   Ando, Kenji ^a   Nobuyoshi, Masakiyo ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

Author keywords

Drug eluting stent; Endovascular therapy; Inflammation; Neointimal thickness; Neovascularization; Optical coherence tomography; Stent apposition; Superficial femoral artery; Vascular response

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; ALLOY; CARDIOVASCULAR AGENT; NITINOL;

AGED; ARTERY LESION; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG ELUTING NITINOL STENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; INTERMITTENT CLAUDICATION; MALE; NEOINTIMA; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PACLITAXEL ELUTING SUPERFICIAL FEMORAL ARTERY NITINOL STENT; PRIORITY JOURNAL; STENT THROMBOSIS; SUPERFICIAL FEMORAL ARTERY; SUPERFICIAL FEMORAL ARTERY LESION; SUPERFICIAL FEMORAL ARTERY STENT; ADVERSE EFFECTS; DRUG ELUTING STENT; FEMORAL ARTERY; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLOYS; CARDIOVASCULAR AGENTS; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; NEOINTIMA; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84935902959     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602814566577     Document Type: Article

References (30)

1. Al-Omran M, Tu JV, Johnston KW, et al. Use of interventional procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: A population-based study. J Vasc Surg. 2003; 38: 289-295.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45(suppl S): S5-S67.
3. Laird JR, Katzen BT, Scheinert D, et al; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010; 3: 267-276.
4. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007; 115: 2745-2749.
5. Dake MD, Ansel GM, Jaff MR, et al; Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013; 18: 2417-2427.
6. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013; 6: 274-281.
7. Ishihara T, Iida O, Awata M, et al. Angioscopically apparent large thrombus and uncovered stent struts 6 months after late stent thrombosis of a paclitaxel-coated nitinol drug-eluting stent implanted in the superficial femoral artery. Cardiovasc Interv Ther. 2014; 29: 82-85.
8. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48: 193-202.
9. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation. 2007; 115: 2435-2441.
10. Dake M, Van Alstine W, Zhou Q, et al. Polymer-free paclitaxel-coated Zilver PTX Stents-evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011; 22: 603-610.
11. Sawada T, Shite J, Negi N, et al. Factors that influence measurements and accurate evaluation of stent apposition by optical coherence tomography. Assessment using a phantom model. Circ J. 2009; 73: 1841-1847.
12. Otake H, Shite J, Shinke T, et al. Impact of stent platform of paclitaxel-eluting stents: Assessment of neointimal distribution on optical coherence tomography. Circ J. 2012; 76: 1880-1888.
13. Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol. 2006; 97: 1713-1717.
14. Takano M, Yamamoto M, Inami S, et al. Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol. 2009; 55: 26-32.
15. Takano M, Yamamoto M, Mizuno M, et al. Late vascular responses from 2 to 4 years after implantation of sirolimuseluting stents. Circ Cardiovasc Interv. 2010; 3: 476-483.
16. Otake H, Shite J, Ikeno F, et al. Evaluation of the peri-strut low intensity area following sirolimus-and paclitaxel-eluting stents implantation: Insights from an optical coherence tomography study in humans. Int J Cardiol. 2012; 157: 38-42.
17. Takano M, Murakami D, Yamamoto M, et al. Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: Comparison with paclitaxel-eluting stents. Int J Cardiol. 2013; 166: 181-186.
18. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008; 52: 333-342.
19. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation. 2006; 113: 414-419.
20. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009; 120: 391-399.
21. Nakazawa G, Finn AV, Vorpahl M, et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus-and paclitaxel-eluting stents. J Am Coll Cardiol. 2011; 57: 390-398.
22. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001; 104: 473-479.
23. Willson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimusand paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009; 120: 141-149.
24. Teramoto T, Ikeno F, Otake H, et al. Intriguing peri-strut lowintensity area detected by optical coherence tomography after coronary stent deployment. Circ J. 2010; 74: 1257-1259.
25. Imai M, Kadota K, Goto T, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011; 123: 2382-2391.
26. Habara M, Terashima M, Nasu K, et al. Difference of tissue characteristics between early and very late restenosis lesions after bare-metal stent implantation: An optical coherence tomography study. Circ Cardiovasc Interv. 2011; 4: 232-238.
27. Paraskevopoulos I, Spiliopoulos S, Davlouros P, et al. Evaluation of below-The-knee drug-eluting stents with frequency-domain optical coherence tomography: Neointimal hyperplasia and neoatherosclerosis. J Endovasc Ther. 2013; 20: 80-93.
28. Nakazawa G, Vorpahl M, Finn AV, et al. One step forward and two steps back with drug-eluting-stents: From preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging. 2009; 2: 625-628.
29. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants baremetal and drug-eluting stents. J Am Coll Cardiol. 2011; 57: 1314-1322.
30. Ishihara T, Iida O, Awata M, et al. Angioscopic assessment of early phase arterial repair after paclitaxel-coated nitinol drugeluting stent implantation in the superficial femoral artery. Circ J. 2013; 77: 1838-1843.